We conclude that GPX4-mediated redox defense, alone or in combination with therapies such as carboplatin, is an actionable target for treatment of TNBC, particularly in patients with obesity. This evidence concerns the gene GPX4 and obesity due to melanocortin 4 receptor deficiency.